Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
To determine a safe and effective doses of two biologic drugs, erlotinib and bevacizumab when
used with chemotherapy and radiation therapy in advanced head and neck cancer
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University